[{"indications": "Indications\u00a0capsules, tablets, and injection: AV nodal reciprocating\r\ntachycardia, arrhythmias associated with accessory conducting pathways\r\n(e.g. Wolff-Parkinson-White syndrome), disabling symptoms of paroxysmal\r\natrial fibrillation in patients without left ventricular dysfunction\r\n(arrhythmias of recent onset will respond more readily)Immediate-release tablets only: symptomatic\r\nsustained ventricular tachycardia, disabling symptoms of premature\r\nventricular contractions or non-sustained ventricular tachycardia\r\nin patients resistant to or intolerant of other therapyInjection only: ventricular tachyarrhythmias\r\nresistant to other treatment", "name": "FLECAINIDE ACETATE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.3 Anti-arrhythmic drugs", "2.3.2 Drugs for arrhythmias", "Supraventricular and ventricular arrhythmias", "FLECAINIDE ACETATE", "Modified release"], "cautions": "Cautions\u00a0patients with pacemakers (especially\r\nthose who may be pacemaker dependent because stimulation threshold\r\nmay rise appreciably); atrial fibrillation\r\nfollowing heart surgery; elderly (accumulation may occur); ECG monitoring and resuscitation\r\nfacilities must be available during intravenous use; interactions: Appendix 1 (flecainide)", "side-effects": "Side-effects\u00a0oedema, pro-arrhythmic effects; dyspnoea; dizziness,\r\nasthenia, fatigue, fever; visual disturbances; rarely pneumonitis, hallucinations, depression, confusion, amnesia, dyskinesia,\r\nconvulsions, peripheral neuropathy; also reported gastro-intestinal disturbances, anorexia, hepatic dysfunction, flushing,\r\nsyncope, drowsiness, tremor, vertigo, headache, anxiety, insomnia,\r\nataxia, paraesthesia, anaemia, leucopenia, thrombocytopenia, corneal\r\ndeposits, tinnitus, increased antinuclear antibodies, hypersensitivity\r\nreactions (including rash, urticaria, and photosensitivity), increased\r\nsweating", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200795.htm", "doses": ["By mouth (initiated under direction\r\nof hospital consultant), ventricular arrhythmias, initially 100\u00a0mg\r\ntwice daily (max. 400\u00a0mg daily usually reserved for rapid control\r\nor in heavily built patients), reduced after 3\u20135 days to the lowest\r\ndose that controls arrhythmia", "Supraventricular arrhythmias, 50\u00a0mg twice daily, increased if\r\nrequired to max. 300\u00a0mg daily", "By slow intravenous injection (in\r\nhospital), 2\u00a0mg/kg over 10\u201330 minutes, max. 150\u00a0mg, with ECG monitoring;\r\nfollowed if required by infusion at a rate of 1.5\u00a0mg/kg/hour\r\nfor 1\u00a0hour, subsequently reduced to 100\u2013250\u00a0micrograms/kg/hour for\r\nup to 24 hours; max. cumulative dose in first 24 hours, 600\u00a0mg; transfer\r\nto oral treatment, as above", "Name[Tambocor\u00ae XL (Meda) ] Capsules, m/r, grey/pink, flecainide\r\nacetate 200\u00a0mg, net price 30-cap pack = \u00a314.77. \r\n    Label:\r\n    25Dose\u00a0supraventricular arrhythmias, 200\u00a0mg once dailyNote\u00a0Not to be used to control arrhythmias in\r\nacute situations; patients stabilised on 200\u00a0mg daily immediate-release\r\nflecainide may be transferred to Tambocor\u00ae XL"], "pregnancy": "Pregnancy\u00a0used in pregnancy to treat maternal and fetal arrhythmias\r\nin specialist centres; toxicity reported in animal studies; infant hyperbilirubinaemia also reported"}, {"indications": "Indications\u00a0capsules, tablets, and injection: AV nodal reciprocating\r\ntachycardia, arrhythmias associated with accessory conducting pathways\r\n(e.g. Wolff-Parkinson-White syndrome), disabling symptoms of paroxysmal\r\natrial fibrillation in patients without left ventricular dysfunction\r\n(arrhythmias of recent onset will respond more readily)Immediate-release tablets only: symptomatic\r\nsustained ventricular tachycardia, disabling symptoms of premature\r\nventricular contractions or non-sustained ventricular tachycardia\r\nin patients resistant to or intolerant of other therapyInjection only: ventricular tachyarrhythmias\r\nresistant to other treatment", "name": "FLECAINIDE ACETATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.3 Anti-arrhythmic drugs", "2.3.2 Drugs for arrhythmias", "Supraventricular and ventricular arrhythmias", "FLECAINIDE ACETATE"], "cautions": "Cautions\u00a0patients with pacemakers (especially\r\nthose who may be pacemaker dependent because stimulation threshold\r\nmay rise appreciably); atrial fibrillation\r\nfollowing heart surgery; elderly (accumulation may occur); ECG monitoring and resuscitation\r\nfacilities must be available during intravenous use; interactions: Appendix 1 (flecainide)", "side-effects": "Side-effects\u00a0oedema, pro-arrhythmic effects; dyspnoea; dizziness,\r\nasthenia, fatigue, fever; visual disturbances; rarely pneumonitis, hallucinations, depression, confusion, amnesia, dyskinesia,\r\nconvulsions, peripheral neuropathy; also reported gastro-intestinal disturbances, anorexia, hepatic dysfunction, flushing,\r\nsyncope, drowsiness, tremor, vertigo, headache, anxiety, insomnia,\r\nataxia, paraesthesia, anaemia, leucopenia, thrombocytopenia, corneal\r\ndeposits, tinnitus, increased antinuclear antibodies, hypersensitivity\r\nreactions (including rash, urticaria, and photosensitivity), increased\r\nsweating", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2427.htm", "doses": ["By mouth (initiated under direction\r\nof hospital consultant), ventricular arrhythmias, initially 100\u00a0mg\r\ntwice daily (max. 400\u00a0mg daily usually reserved for rapid control\r\nor in heavily built patients), reduced after 3\u20135 days to the lowest\r\ndose that controls arrhythmia", "Supraventricular arrhythmias, 50\u00a0mg twice daily, increased if\r\nrequired to max. 300\u00a0mg daily", "By slow intravenous injection (in\r\nhospital), 2\u00a0mg/kg over 10\u201330 minutes, max. 150\u00a0mg, with ECG monitoring;\r\nfollowed if required by infusion at a rate of 1.5\u00a0mg/kg/hour\r\nfor 1\u00a0hour, subsequently reduced to 100\u2013250\u00a0micrograms/kg/hour for\r\nup to 24 hours; max. cumulative dose in first 24 hours, 600\u00a0mg; transfer\r\nto oral treatment, as above"], "pregnancy": "Pregnancy\u00a0used in pregnancy to treat maternal and fetal arrhythmias\r\nin specialist centres; toxicity reported in animal studies; infant hyperbilirubinaemia also reported"}]